Table 3 Univariate and multivariate Cox proportional hazard regression analysis for progression to ESRD

Male gender

1.163 (0.665-2.034)

0.596

Age65≥yr (versus <65yr)

1.605 (0.899-2.867)

0.110

Hemoglobin<90g/L (versus ≥90g/L)

2.749 (1.453-5.202)

0.002

Creatinine≥500μmol/L (versus<500μmol/L)

8.330 (4.515-15.368)

<0.001

8.236 (4.340-15.630)

<0.001

Albumin<30g/L (versus ≥30g/L)

0.832 (0.477-1.450)

0.832

General manifestation (Myalgia, Arthritis, Fever≥38°C, Weight loss≥2kg)

0.437 (0.247-0.775)

0.005

Cutaneous involvement

0.042 (0.000-3.749)

0.167

Involvement of mucous membranes/eyes

2.265 (0.309-16.587)

0.421

Involvement of ear, nose, and throat (ENT)

2.826 (0.387-20.631)

0.306

Interstitial lung disease

1.793 (1.020-3.152)

0.042

2.649 (1.461-4.802)

0.001

Alveolar hemorrhage

1.975 (1.030-3.785)

0.040

Cardiovascular involvement

1.519 (0.713-3.236)

0.279

Abdominal involvement

1.347 (0.184-9.866)

0.769

Nervous system involvement

0.470 (0.186-1.185)

0.110

BVAS

1.062 (1.011-1.114)

0.016

Immunosuppressive treatment

0.296 (0.168-0.520)

<0.001

0.349 (0.192-0.634)

0.001

Coronary heart disease

2.318 (1.125-4.775)

0.023

Heart failure

2.448 (0.871-6.878)

0.089

Chronic obstructive pulmonary disease

0.348 (0.048-2.523)

0.296

Liver disease

1.116 (0.154-8.095)

0.914

Peptic ulcer

1.491 (0.590-3.765)

0.398

Diabetes

1.655 (0.776-3.526)

0.192